表紙
市場調査レポート

プレシジョンメディシン (精密医療) の世界市場の推計・予測 (2015-2022年):エコシステム・技術区分・疾患区分・地域別

Global Precision Medicine Market: Focus On Ecosystem, Sub-markets, Therapeutics Application & Regions - Estimate and Forecast 2015-2022

発行 BIS Research 商品コード 345248
出版日 ページ情報 英文 280 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
プレシジョンメディシン (精密医療) の世界市場の推計・予測 (2015-2022年):エコシステム・技術区分・疾患区分・地域別 Global Precision Medicine Market: Focus On Ecosystem, Sub-markets, Therapeutics Application & Regions - Estimate and Forecast 2015-2022
出版日: 2015年11月17日 ページ情報: 英文 280 Pages
概要

プレシジョンメディシン (精密医療) は医療部門の中でもっとも新しいトレンドのひとつとなっており、近年大幅な成長を遂げています。政府によるイニシアチブやR&Dプログラムが近年になって多数開始されており、これが市場成長を加速させています。同市場の規模は2015年から2022年にかけて12.60%のCAGRで推移し、2022年には880億ドルを超える規模に成長すると予測されています。

当レポートでは、世界のプレシジョンメディシン (精密医療) の市場について調査し、精密医療の定義と市場の構成、市場の発展の経緯、産業構造とバリューチェーン、市場成長への各種影響因子の分析、法規制・規制当局・関連団体・各種承認・標準規格、参入事業者区分・技術区分・疾患区分・地域別の主要動向および市場規模の推移と予測、主要企業のプロファイルなどをまとめています。

第1章 調査範囲

第2章 エグゼクティブサマリー

第3章 市場概要

  • イントロダクション
  • 市場のタイムライン
  • 主な参入事業者&機関・戦略・発展状況
    • 政府機関
    • 学術機関
    • デバイス&サービスプロバイダー
  • 主な市場戦略・発展状況
    • イントロダクション
    • 提携・合意・協力
    • M&A
    • 製品の開発・投入
    • 事業の拡張・縮小
    • 特許・認証
    • その他

第4章 市場力学

  • イントロダクション
  • 市場成功推進因子
  • 市場課題
  • 市場機会

第5章 産業力学

  • バリューチェーン分析
  • ポーターのファイブフォース分析

第6章 コンソーシアム・認証・法規制・標準規格

  • イントロダクション
    • 規制当局
    • コンソーシアム
    • アライアンス/アソシエーション

第7章 市場分析:参入事業者区分別

  • イントロダクション
    • 市場統計
  • 医薬品・バイオテクノロジー企業
    • 主な市場動向・発展状況・参入事業者
  • 診断関連企業
    • 主な市場動向・発展状況・参入事業者
  • 医療用IT・ビッグデータ関連事業者
    • 主な市場動向・発展状況・参入事業者
  • 臨床ラボ
    • 主な市場動向・発展状況・参入事業者

第8章 市場分析:構成区分別

  • イントロダクション
    • 市場統計
  • コンパニオン診断
  • バイオマーカーによる検査
    • バイオバンキングとバイオマーカー
    • 主な参入事業者
  • 標的治療
    • 主な参入事業者
  • ファーマコゲノミクス (PGX)
    • 主な市場動向・発展状況・参入事業者
  • 分子診断
  • その他
    • 次世代シーケンシング
    • コンシューマーゲノミクス
      • 主な参入事業者
    • 3Dプリンティング
    • 補綴市場
    • ヒト組織市場

第9章 市場分析:疾患区分別

  • イントロダクション
    • 市場統計
    • 市場統計
    • 癌の各種タイプ
    • 薬剤・検査
    • 主な市場動向・発展状況・参入事業者
  • 心血管系疾病 (CVD)
    • 市場統計
    • 薬剤・検査
    • 市場動向・発展状況
  • 中枢神経系疾患
    • 市場統計
    • 神経系
      • 薬剤・検査
    • 精神系
      • 薬剤・検査
    • 市場動向・発展状況
  • 感染症
    • 市場統計
    • 薬剤・検査
    • 市場発展状況・参入事業者
  • その他
    • 市場統計
    • 主な市場動向・発展状況・参入事業者

第10章 市場分析:地域別

  • イントロダクション
    • 市場統計
  • 南北アメリカ
    • 北米
      • 主な市場動向・発展状況・参入事業者
      • 法規制・コンプライアンス
    • 南米
      • 主な市場動向・発展状況・参入事業者
      • 法規制・コンプライアンス
  • 欧州
    • 主な市場動向・発展状況・参入事業者
      • 法規制・コンプライアンス
  • アジア太平洋
    • 主な市場動向・発展状況・参入事業者
  • その他/中東・アフリカ
    • 主な市場動向・発展状況・参入事業者

第11章 企業プロファイル

  • ABBOTT LABORATORIES
  • ALMAC GROUP, LTD.
  • ASURAGEN, INC.
  • BIOMERIEUX SA
  • CEPHEID INC.
  • CETICS HEALTHCARE TECHNOLOGIES GMBH
  • GE HEALTHCARE
  • GLAXOSMITHKLINE PLC (GSK)
  • INTOMICS A/S
  • JOHNSON & JOHNSON
  • LABORATORY CORPORATION OF AMERICA HOLDINGS
  • MEDTRONIC
  • NOVARTIS
  • PFIZER INC.
  • QIAGEN
  • QUEST DIAGNOSTICS INC
  • RANDOX LABORATORIES LTD.
  • ROCHE HOLDING AG-BR
  • SANOFI PHARMA
  • 武田薬品工業
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • AB-BIOTICS SA
  • CARIS LIFE SCIENCES
  • HEALTHCORE, INC.
  • IBM
  • INNVENTIS
  • INTEL CORPORATION
  • MOLECULAR HEALTH GMBH
  • PRECISION FOR MEDICINE

図表

目次
Product Code: MD05

The advancement and innovation of new healthcare technologies are developing the platform for the growth of precision medicine market. Since, the announcement of 'Precision Medicine Initiative' by the President Barack Obama in January, 2015, a large number of research and development has been taken for the development of precise drugs, targeted therapeutics, and laboratory tests. Presently, the main focus of the government initiatives is toward oncology, but it is anticipated to target almost all therapeutic areas affected by genetic mutations.

Governmental regulations and standards are sustaining the growth and development of the precision medicine market. The main aim of these regulations is to make precision medicines more adaptable and focused towards genetic diseases related to Oncology, skin, respiratory, CNS, CVD, and infectious diseases among others. The patients are benefitted indirectly by these regulations as it save time and cut-down cost as the patients get the required treatment for the specific disease.

The growth in the precision medicine market is propelled by an increasing demand for personalized treatment, technological innovation and advancement (including Biomarker-based tests/kits, next gene sequencing, and precise imaging), Government support and regulations, and these have created a demand for the precision medicine solutions.

Our study includes an overview and analysis of the precision medicine market by ecosystem, sub-markets, therapeutics and geographical regions, allowing the research to develop a comprehensive outlook of the market. The precision medicine market report presents detailed analysis of the entire precision medicine ecosystem and provides extensive insights of the different developments, trends and key participants. The report also focuses on different sub-markets which help in the development of precision medicine solutions. The sub-market verticals are categorized into five major categories, viz. companion diagnostics, biomarkers, targeted therapeutics, Pharmacogenomics and molecular diagnostics among others in the report.

Further, the scope of the report includes the therapeutics of different disease types managed by this technology. All of the above mentioned report coverage parameters are discussed across different regions like The Americas, Europe, Asia Pacific (APAC) and Rest of the World (ROW).

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliance, and regulatory bodies and their involvement in the precision medicine market.

The answers to the following key questions can be found in the report:

  • What are the major market drivers, challenges and opportunities of the precision medicine market and their use cases?
  • What are the primary precision medicine market trends and key developments for different precision medicine systems?
  • What are the key developmental strategies in different applications across all regions in this market?
  • What are different types of precision medicine solutions and the latest precision medicine technologies?
  • How will the key market players leverage on key developments such as Mergers and Acquisitions, Partnerships, and Product Launches among others?
  • Which geographical region will lead the global precision medicine market by the end of the forecast period?
  • Who are the key players in the precision medicine market?
  • What kind of government regulations have been implemented for different precision medicine solutions?
  • What are the different types of sub-markets in precision medicine market and what are the applications in which they are being used?
  • What is the different used case scenarios considered under different applications?
  • What are the different therapeutic applications in which precision medicine products are being used?
  • What are the precision medicine market trends and key developments in different geographical regions?

This research tries to answer various aspects of the precision medicine market such as major factors driving the market, threats that can possibly slow down the market growth, and the current growth opportunities that are going to shape the market expansion of precision medicine solutions. The research study incorporates Porter's Five Force Model for in-depth analysis of the precision medicine market and an assessment of the factors governing it. The report builds itself upon a comprehensive value chain giving a clear understanding of ecosystem of precision medicine market penetration.

Towards the end of the report, the readers will have a clear understanding of the market dynamics, major drivers and the underlying threats and challenges that the global precision medicine industry is subjected to, including the estimation of the industry's growth in terms of production and revenue.

The report includes the profiles of major players in the precision medicine market that allows its readers to get an insight into the industry trends. Some of the leading companies in the precision medicine market are Abbott Laboratories, Almac Group Ltd. and Caris Life sciences among others.

Executive Summary

Precision medicine is becoming one of the most modernized trends in the healthcare industry showing an incredible growth in the recent years. The market growth is gaining speed as large number of government initiatives and research & development programs have been launched in the recent years. According to the report put forward by the market research experts of BIS Research, the global precision medicine market is expected to grow over $88 billion by 2022 at an estimated CAGR of 12.60% from 2015 to 2022.

While The Americas will continue to lead the global market through the forecast period, Europe and APAC will continue to be the principal revenue generating countries of the world. The global precision medicine market, on the basis of sub-market categories, is segmented into: companion diagnostics, biomarkers, targeted therapeutics, pharmacogenomics, molecular diagnostics and others. With increasing research and development processes, it has been estimated that the demand for precision drugs will escalate in the coming future, thus, resulting in the domination of the Pharma & Biotech segment. At present, Cancer is dominating the market and is expected to reach $46.38 billion by 2022, as the number of cancer patients are increasing every year and thus, deployment of targeted therapeutics and diagnosis applications of cancer is also anticipated to increase tremendously.

Primarily, the reason attributed to the growth of the precision medicine therapeutics market is due to the increase in cancer cases, cardiac diseases, skin diseases, mental disorders, and other gene related issues. In Americas have existing players who are integrating with new start-ups through partnerships and collaboration so as to capture the North American segment. North American local players are entering to capture the South American precision medicine market. Throughout the Asia-Pacific countries, regulatory bodies are rolling out regulations to keep a check on latest technologies.

Table of Contents

1 REPORT SCOPE

  • 1.1 SCOPE OF THE STUDY
  • 1.2 PRECISION MEDICINE: REPORT COVERAGE
  • 1.3 BIS RESEARCH METHODOLOGY
    • 1.3.1 RESEARCH METHODOLOGY FOR THE GLOBAL MARKET STUDY
      • 1.3.1.1 Geographical Analysis
      • 1.3.1.2 Demand Side & Supply Side Analysis
      • 1.3.1.3 Data Synthesis and Bridging
    • 1.3.2 GLOBAL PRECISION MEDICINE: RESEARCH METHODOLOGY
    • 1.3.3 KEY DATA POINT SOURCES
      • 1.3.3.1 Data Points taken from Secondary Sources
      • 1.3.3.2 Data Points taken from Primary Sources
  • 1.4 REPORT DESCRIPTION

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW

  • 3.1 INTRODUCTION
  • 3.2 MARKET TIMELINE
  • 3.3 KEY PARTICIPANTS, STRATEGIES & DEVELOPMENTS
    • 3.3.1 GOVERNMENT AGENCIES
    • 3.3.2 ACADEMIC INSTITUTIONS
    • 3.3.3 DEVICE & SERVICE PROVIDERS
  • 3.4 KEY MARKET STRATEGIES AND DEVELOPMENTS
    • 3.4.1 INTRODUCTION
    • 3.4.2 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
    • 3.4.3 MERGERS & ACQUISITIONS
    • 3.4.4 PRODUCT DEVELOPMENT AND LAUNCH
    • 3.4.5 BUSINESS EXPANSION/CONTRACTS
    • 3.4.6 PATENTS, APPROVALS AND CERTIFICATIONS
    • 3.4.7 OTHERS (EVENTS & RECOGNITIONS)

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 MARKET DRIVERS
    • 4.2.1 PATIENTS INVOLVEMENT IN PERSONAL HEALTHCARE
    • 4.2.2 TECHNOLOGIES DRIVING THE MARKET (E.G. NEXT-GENERATION SEQUENCING TECHNOLOGIES, ULTRA-HIGH THROUGHPUT SEQUENCING)
    • 4.2.3 INCREASE IN GENETIC DISEASES
    • 4.2.4 POTENTIAL FOR MORE TARGETED THERAPIES
    • 4.2.5 INTEGRATION OF BIG DATA HEALTHCARE COMPANIES WITH PHARMA & BIOTECH COMPANIES
  • 4.3 MARKET CHALLENGES
    • 4.3.1 POTENTIAL THREAT TO PERSONAL DATA
    • 4.3.2 HIGH DIAGNOSTIC COST AS A BARRIER
    • 4.3.3 POTENTIAL RISK OF HARDWARE OR SOFTWARE FAILURE
    • 4.3.4 STRINGENT REGULATIONS AND STANDARDS
    • 4.3.5 LACK OF AWARENESS ABOUT THE POSSIBLE APPLICATIONS OF PRECISION MEDICINE
    • 4.3.6 REIMBURSEMENT POLICIES AND REGULATORY FRAMEWORK
    • 4.3.7 LIMITED KNOWLEDGE ABOUT THE APPLICATION OF TEST AND TECHNIQUES
    • 4.3.8 LACK OF RESEARCH AND EVIDENCES CREATING HINDRANCES IN ITS APPLICATION
  • 4.4 MARKET OPPORTUNITIES
    • 4.4.1 INTRODUCTION OF PRECISION MEDICINE SOLUTIONS IN DEVELOPING ECONOMIES
    • 4.4.2 DOWNSIZING THE COST OF GENOME SEQUENCING TO THREE DIGITS

5 INDUSTRY DYNAMICS

  • 5.1 VALUE CHAIN ANALYSIS
    • 5.1.1 DEVICE MANUFACTURER & DRUG PRODUCERS
    • 5.1.2 HEALTHCARE PROVIDERS
    • 5.1.3 HEALTHCARE ITS OR BIG DATA COMPANIES
    • 5.1.4 REGULATORS
    • 5.1.5 THIRD PARTY PAYERS
    • 5.1.6 PATIENTS
  • 5.2 PORTER FIVE FORCE ANALYSIS
    • 5.2.1 BARGAINING POWER OF BUYER (PATIENT)
    • 5.2.2 BARGAINING POWER OF SUPPLIER
    • 5.2.3 THREAT FROM SUBSTITUTE
    • 5.2.4 THREAT FROM A NEW ENTRANT
    • 5.2.5 INTENSITY OF COMPETITIVE RIVALRY

6 CONSORTIUMS, CERTIFICATION, REGULATIONS, AND STANDARDS

  • 6.1 INTRODUCTION
    • 6.1.1 REGULATORY BODIES
      • 6.1.1.1 Food and Drug Administration (FDA)
      • 6.1.1.2 Medicines and Healthcare products Regulatory Agency (MHRA)
      • 6.1.1.3 Therapeutic Goods Administration (TGA)-Australia
      • 6.1.1.4 Conformité Européenne (CE)
    • 6.1.2 CONSORTIUMS
    • 6.1.3 ALLIANCES/ASSOCIATIONS

7 GLOBAL PRECISION MEDICINE MARKET BY ECOSYSTEM PLAYERS

  • 7.1 INTRODUCTION
    • 7.1.1 MARKET STATISTICS
  • 7.2 PHARMACEUTICALS AND BIOTECHNOLOGY COMPANIES
    • 7.2.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
      • 7.2.1.1 Market Trends
      • 7.2.1.2 Market Developments
      • 7.2.1.3 Key Participants
  • 7.3 DIAGNOSTIC COMPANIES
    • 7.3.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
      • 7.3.1.1 Market Trends
      • 7.3.1.2 Market Developments
      • 7.3.1.3 Key Participants
    • 7.4 HEALTHCARE IT SPECIALISTS/ BIG DATA COMPANIES
    • 7.4.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
      • 7.4.1.1 Market Trends
      • 7.4.1.2 Market Developments
      • 7.4.1.3 Key Participants
  • 7.5 CLINICAL LABORATORIES
    • 7.5.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
      • 7.5.1.1 Regulatory bodies and compliances
      • 7.5.1.2 Market Trends
      • 7.5.1.3 Key Participants

8 GLOBAL PRECISION MEDICINE MARKET BY SUB-MARKETS

  • 8.1 INTRODUCTION
    • 8.1.1 MARKET STATISTICS
  • 8.2 COMPANION DIAGNOSTICS
  • 8.3 BIOMARKER-BASED TEST
    • 8.3.1 ROLE OF BIOBANKING INTO BIOMARKER
    • 8.3.2 KEY PARTICIPANTS
  • 8.4 TARGETED THERAPEUTICS
    • 8.4.1 KEY PARTICIPANTS
  • 8.5 PHARMACOGENOMICS (PGX)
    • 8.5.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
      • 8.5.1.1 Market Trends
      • 8.5.1.2 Market Developments
      • 8.5.1.3 Key Participants
  • 8.6 MOLECULAR DIAGNOSTICS
  • 8.7 OTHERS
    • 8.7.1 NEXT-GENERATION SEQUENCING
    • 8.7.2 CONSUMER GENOMICS
      • 8.7.2.1 Key Participants
    • 8.7.3 3D PRINTING
    • 8.7.4 PROSTHETICS MARKET
    • 8.7.5 HUMAN TISSUES MARKET

9 GLOBAL PRECISION MEDICINE MARKET BY THERAPEUTICS

  • 9.1 INTRODUCTION
    • 9.1.1 MARKET STATISTICS
  • 9.2 CANCER/ONCOLOGY
    • 9.2.1 MARKET STATISTICS
    • 9.2.2 TYPES OF CANCER
    • 9.2.3 DRUGS & TESTS
    • 9.2.4 KEY MARKET TRENDS, DEVELOPMENTS & PARTICIPANTS
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Developments
      • 9.2.4.3 Key Participants
  • 9.3 CARDIOVASCULAR DISEASE (CVD)
    • 9.3.1 MARKET STATISTICS
    • 9.3.2 DRUGS & TESTS
    • 9.3.3 MARKET TRENDS & MARKET DEVELOPMENTS
      • 9.3.3.1 Market trend
      • 9.3.3.2 Market Developments
      • 9.3.3.3 Key Participants
  • 9.4 CENTRAL NERVOUS SYSTEM
    • 9.4.1 MARKET STATISTICS
    • 9.4.2 NEUROLOGICAL
      • 9.4.2.1 Neurological Drugs & Tests
    • 9.4.3 PSYCHIATRIC DISORDERS
      • 9.4.3.1 Psychiatric Disorder Drugs & Tests
    • 9.4.4 MARKET TENDS & MARKET DEVELOPMENTS
      • 9.4.4.1 Market Trends
      • 9.4.4.2 Key Developments
      • 9.4.4.3 Key Participants
  • 9.5 INFECTIOUS DISEASES
    • 9.5.1 MARKET STATISTICS
    • 9.5.2 INFECTIOUS DISEASES DRUGS & TESTS
    • 9.5.3 MARKET DEVELOPMENTS & PARTICIPANTS
      • 9.5.3.1 Key Developments
      • 9.5.3.2 Key Participants
  • 9.6 OTHERS
    • 9.6.1 MARKET STATISTICS
    • 9.6.2 MARKET TRENDS, DEVELOPMENTS & PARTICIPANTS
      • 9.6.2.1 Market Trends
      • 9.6.2.2 Key Developments
      • 9.6.2.3 Key Participants

10 GLOBAL PRECISION MEDICINE MARKET BY GEOGRAPHY

  • 10.1 INTRODUCTION
    • 10.1.1 MARKET STATISTICS
  • 10.2 THE AMERICAS
    • 10.2.1 NORTH AMERICA
      • 10.2.1.1 The U.S.
      • 10.2.1.2 Canada
      • 10.2.1.3 Others
      • 10.2.1.4 Key Market Trends, Developments and Participants
      • 10.2.1.5 Regulations and Compliances
      • 10.2.1.6 Market Trends
      • 10.2.1.7 Market Developments
      • 10.2.1.8 Key Participants
    • 10.2.2 SOUTH AMERICA
      • 10.2.2.1 Key Market Trends, Developments and Participants
      • 10.2.2.2 Regulations and Compliances
      • 10.2.2.3 Market Trends
      • 10.2.2.4 Key Participants
  • 10.3 EUROPE
    • 10.3.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
      • 10.3.1.1 Regulations and Compliances
      • 10.3.1.2 Market Developments
      • 10.3.1.3 Key Participants
  • 10.4 ASIA-PACIFIC (APAC)
    • 10.4.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS
      • 10.4.1.1 Market Developments
      • 10.4.1.2 Key Participants
  • 10.5 REST OF THE WORLD/MIDDE EAST & AFRICA (MEA)
    • 10.5.1 AFRICA
      • 10.5.1.1 Middle East
    • 10.5.2 KEY MARKET DEVELOPMENTS AND PARTICIPANTS
      • 10.5.2.1 Market Developments
      • 10.5.2.2 Key Participants

11 COMPANY PROFILES

  • 11.1 ABBOTT LABORATORIES
    • 11.1.1 OVERVIEW
    • 11.1.2 FINANCIALS
      • 11.1.2.1 Overall Financials
      • 11.1.2.2 Financials by Segment
      • 11.1.2.3 Financials by Region
      • 11.1.2.4 Key Developments
    • 11.1.3 SWOT ANALYSIS
  • 11.2 ALMAC GROUP, LTD.
    • 11.2.1 OVERVIEW
    • 11.2.2 FINANCIALS
    • 11.2.3 KEY DEVELOPMENTS
    • 11.2.4 SWOT ANALYSIS
  • 11.3 ASURAGEN, INC.
    • 11.3.1 OVERVIEW
    • 11.3.2 FINANCIALS
    • 11.3.3 KEY DEVELOPMENTS
    • 11.3.4 SWOT ANALYSIS
  • 11.4 BIOMÉRIEUX SA
    • 11.4.1 OVERVIEW
    • 11.4.2 FINANCIALS
      • 11.4.2.1 Overall Financials
      • 11.4.2.2 Financials By Region
      • 11.4.2.3 Financials By Segment
    • 11.4.3 KEY DEVELOPMENTS
    • 11.4.4 SWOT ANALYSIS
  • 11.5 CEPHEID INC.
    • 11.5.1 OVERVIEW
    • 11.5.2 FINANCIALS
      • 11.5.2.1 Overall Financials
      • 11.5.2.2 NET REVENUE BY SEGMENT
      • 11.5.2.3 NET REVENUE BY REGION
    • 11.5.3 KEY DEVELOPMENTS
    • 11.5.4 SWOT ANALYSIS
  • 11.6 CETICS HEALTHCARE TECHNOLOGIES GMBH
    • 11.6.1 OVERVIEW
    • 11.6.2 FINANCIALS
    • 11.6.3 KEY DEVELOPMENTS
    • 11.6.4 SWOT ANALYSIS
  • 11.7 GE HEALTHCARE
    • 11.7.1 OVERVIEW
    • 11.7.2 FINANCIALS
      • 11.7.2.1 Overall financials
      • 11.7.2.2 NET REVENUE BY SEGMENT
      • 11.7.2.3 Financial Summary
    • 11.7.3 KEY DEVELOPMENTS
  • 11.8 GLAXOSMITHKLINE PLC (GSK)
    • 11.8.1 OVERVIEW
    • 11.8.2 FINANCIALS
      • 11.8.2.1 Overall Financials
      • 11.8.2.2 Financials By Segment
      • 11.8.2.3 Financials By Region
      • 11.8.2.4 Financials By Therapeutics
  • 11.9 INTOMICS A/S
    • 11.9.1 OVERVIEW
    • 11.9.2 FINANCIALS
    • 11.9.3 KEY DEVELOPMENTS
    • 11.9.4 SWOT ANALYSIS
  • 11.10 JOHNSON & JOHNSON
    • 11.10.1 OVERVIEW
    • 11.10.2 FINANCIALS
      • 11.10.2.1 Overall Financials
      • 11.10.2.2 Net Revenue By Segment
      • 11.10.2.3 Net revenue by Region
    • 11.10.3 KEY DEVELOPMENTS
  • 11.11 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • 11.11.1 OVERVIEW
    • 11.11.2 FINANCIALS
      • 11.11.2.1 Overall Financials
      • 11.11.2.2 Financials by Segment
    • 11.11.3 KEY DEVELOPMENTS
    • 11.11.4 SWOT ANALYSIS
  • 11.12 MEDTRONIC
    • 11.12.1 OVERVIEW
    • 11.12.2 FINANCIALS
      • 11.12.2.1 Overall Financials
    • 11.12.3 KEY DEVELOPMENTS
  • 11.13 NOVARTIS
    • 11.13.1 OVERVIEW
    • 11.13.2 FINANCIALS
      • 11.13.2.1 Overall Financials
      • 11.13.2.2 Financials By Region
      • 11.13.2.3 Financials By Segment
  • 11.14 PFIZER INC.
    • 11.14.1 OVERVIEW
    • 11.14.2 FINANCIALS
      • 11.14.2.1 Overall Financials
      • 11.14.2.2 NET REVENUE BY SEGMENT
      • 11.14.2.3 NET REVENUE BY REGION
    • 11.14.3 KEY DEVELOPMENTS
    • 11.14.4 SWOT ANALYSIS
  • 11.15 QIAGEN
    • 11.15.1 OVERVIEW
      • 11.15.1.1 BIOBASE Gmbh (subsidiary)
        • 11.15.1.1.1 Overview
    • 11.15.2 FINANCIALS
      • 11.15.2.1 Overall Financials
    • 11.15.3 KEY DEVELOPMENTS(BIOBASE)
  • 11.16 QUEST DIAGNOSTICS INC
    • 11.16.1 OVERVIEW
    • 11.16.2 FINANCIALS
      • 11.16.2.1 Overall Financials
      • 11.16.2.2 NET REVENUE BY SEGMENT
    • 11.16.3 KEY DEVELOPMENTS
    • 11.16.4 SWOT ANALYSIS
  • 11.17 RANDOX LABORATORIES LTD.
    • 11.17.1 OVERVIEW
    • 11.17.2 FINANCIALS
    • 11.17.3 KEY DEVELOPMENTS
    • 11.17.4 SWOT ANALYSIS
  • 11.18 ROCHE HOLDING AG-BR
    • 11.18.1 OVERVIEW
    • 11.18.2 FINANCIALS
      • 11.18.2.1 Overall Financials
      • 11.18.2.2 NET REVENUE BY SEGMENT
    • 11.18.3 KEY DEVELOPMENTS
    • 11.18.4 SWOT ANALYSIS
  • 11.19 SANOFI PHARMA
    • 11.19.1 OVERVIEW
    • 11.19.2 FINANCIALS
      • 11.19.2.1 Overall Financials
      • 11.19.2.2 NET REVENUE BY SEGMENT
  • 11.20 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 11.20.1 OVERVIEW
    • 11.20.2 FINANCIALS
      • 11.20.2.1 Overall Financials
    • 11.20.3 KEY DEVELOPMENTS
    • 11.20.4 SWOT ANALYSIS
  • 11.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 11.21.1 OVERVIEW
    • 11.21.2 FINANCIALS
      • 11.21.2.1 Overall Financials
      • 11.21.2.2 Net Revenue By Segment
      • 11.21.2.3 Net Revenue By Segment
    • 11.21.3 KEY DEVELOPMENTS
    • 11.21.4 SWOT ANALYSIS
  • 11.22 AB-BIOTICS SA
    • 11.22.1 OVERVIEW
  • 11.23 CARIS LIFE SCIENCES
    • 11.23.1 OVERVIEW
  • 11.24 HEALTHCORE, INC.
    • 11.24.1 OVERVIEW
  • 11.25 IBM
    • 11.25.1 OVERVIEW
  • 11.26 INNVENTIS
    • 11.26.1 OVERVIEW
  • 11.27 INTEL CORPORATION
    • 11.27.1 OVERVIEW
  • 11.28 MOLECULAR HEALTH GMBH
    • 11.28.1 OVERVIEW
  • 11.29 PRECISION FOR MEDICINE
    • 11.29.1 OVERVIEW

List of Tables

  • TABLE 1 LEADING COMPANIES IN THE PRECISION MEDICINE MARKET
  • TABLE 2 FACTORS IMPACTING THE BUYER'S BARGAINING POWER
  • TABLE 3 FACTORS IMPACTING THE SUPPLIER'S BARGAINING POWER
  • TABLE 4 FACTORS IMPACTING THE THREAT FROM SUBSTITUTE
  • TABLE 5 FACTORS IMPACTING THE THREAT FROM NEW ENTRANT
  • TABLE 6 REGULATORY BODIES IN PRECISION MEDICINE MARKET
  • TABLE 7 CONSORTIUMS IN PRECISION MEDICINE MARKET
  • TABLE 8 ALLIANCES/ASSOCIATIONSIN PRECISION MEDICINE MARKET
  • TABLE 9 GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)
  • TABLE 10 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)
  • TABLE 11 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION)
  • TABLE 12 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION)
  • TABLE 13 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014- 2022 ($BILLION)
  • TABLE 14 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION)
  • TABLE 15 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION)
  • TABLE 16 KEY DEVELOPMENTS IN DIAGNOSTIC COMPANIES(2015)
  • TABLE 17 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)
  • TABLE 18 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION)
  • TABLE 19 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014- 2022 ($BILLION)
  • TABLE 20 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)
  • TABLE 21 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION)
  • TABLE 22 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014- 2022 ($BILLION)
  • TABLE 23 GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)
  • TABLE 24 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
  • TABLE 25 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)
  • TABLE 26 BENEFITS OF COMPANION DIAGNOSTICS
  • TABLE 27 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
  • TABLE 28 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014- 2022 ($MILLION)
  • TABLE 29 EXAMPLES OF BIOBANKING INITIATIVES ACROSS SELECTED OECD COUNTRIES
  • TABLE 30 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
  • TABLE 31 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)
  • TABLE 32 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
  • TABLE 33 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)
  • TABLE 34 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
  • TABLE 35 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)
  • TABLE 36 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
  • TABLE 37 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION)
  • TABLE 38 GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($BILLION)
  • TABLE 39 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)
  • TABLE 40 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)
  • TABLE 41 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION)
  • TABLE 42 PRECISION MEDICINE DRUGS AND RELEVANT GENES: ONCOLOGY
  • TABLE 43 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO ONCOLOGY
  • TABLE 44 KEY DEVELOPMENTS (2013-2015)
  • TABLE 45 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)
  • TABLE 46 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION)
  • TABLE 47 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 48 PRECISION MEDICINE DRUGS AND RELEVANT GENES: CARDIOVASCULAR
  • TABLE 49 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO CARDIOVASCULAR
  • TABLE 50 KEY DEVELOPMENTS (2014-2015)
  • TABLE 51 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
  • TABLE 52 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($MILLION)
  • TABLE 53 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 54 PRECISION MEDICINE DRUGS AND RELEVANT GENES: NEUROLOGY
  • TABLE 55 PRECISION MEDICINE DRUGS AND RELEVANTGENES: PSYCHIATRIC DISORDERS
  • TABLE 56 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO PSYCHIATRIC DISORDERS
  • TABLE 57 PSYCHIATRIC DISORDERS: KEY DEVELOPMENTS (2014-2015)
  • TABLE 58 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
  • TABLE 59 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($MILLION)
  • TABLE 60 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 61 PRECISION MEDICINE DRUGS AND RELEVANT GENES: INFECTIOUS DISEASES
  • TABLE 62 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
  • TABLE 63 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($MILLION)
  • TABLE 64 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014- 2022 ($MILLION)
  • TABLE 65 PRECISION MEDICINE DRUGS AND RELEVANT GENES: OTHER DISEASES
  • TABLE 66 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO OTHER DISEASES
  • TABLE 67 GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION)
  • TABLE 68 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)
  • TABLE 69 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)
  • TABLE 70 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014- 2022 ($BILLION)
  • TABLE 71 EUROPE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)
  • TABLE 72 EUROPE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014- 2022 ($BILLION)
  • TABLE 73 APAC: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION)
  • TABLE 74 APAC: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($MILLION)
  • TABLE 75 ROW: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION)
  • TABLE 76 ROW: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($MILLION)

List of Figures

  • FIGURE 1 PRECISION MEDICINE MARKET STUDY
  • FIGURE 2 BIS RESEARCH METHODOLOGY
  • FIGURE 3 DIFFERENT PHASES OF RESEARCH METHODOLOGY FOR THE GLOBAL MARKET
  • FIGURE 4 PRECISION MEDICINE MARKET: RESEARCH METHODOLOGY
  • FIGURE 5 GLOBAL PRECISION MEDICINE MARKET SHARE, BY ECOSYSTEM, 2014-2022 ($BILLION)
  • FIGURE 6 GLOBAL PRECISION MEDICINE MARKET SIZE, BY SUB-MARKET TYPE, 2014 - 2022 (BILLION)
  • FIGURE 7 GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERPEUTIC APPLICATION, 2014 - 2022 (BILLION)
  • FIGURE 8 GLOBAL PRECISION MEDICINE MARKET SIZE, BY GEOGRAPHY, 2014 - 2022 ($BILLION)
  • FIGURE 9 TIMELINE OF PRECISION MEDICINE
  • FIGURE 10 PRECISION MEDICINE: BENEFITS
  • FIGURE 11 EXAMPLES: APPLIED AREAS OF PRECISION MEDICINE
  • FIGURE 12 ELEMENTS OF PRECISION MEDICINE TECHNOLOGY
  • FIGURE 13 DIFFERENT TYPE OF DATA USED BY BIG DATA COMPANIES
  • FIGURE 14 PRECISION MEDICINE : AREAS OF INTEREST
  • FIGURE 15 PRECISION MEDICINE: PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2015)
  • FIGURE 16 PRECISION MEDICINE : MERGERS & ACQUISITIONS( 2015)
  • FIGURE 17 PRECISION MEDICINE : KEY PRODUCT LAUNCH & DEVELOPMENTS (2015)
  • FIGURE 18 PRECISION MEDICINE: KEY BUSINESS EXPANSIONS & CONTRACTS (2015)
  • FIGURE 19 PRECISION MEDICINE : KEY PATENTS/ APPROVALS ( 2015)
  • FIGURE 20 PRECISION MEDICINE: EVENTS & RECOGNITION (2015)
  • FIGURE 21 MARKET DRIVERS AND CHALLENGES
  • FIGURE 22 BENEFITS OF PRECISION MEDICINE TO PATIENTS
  • FIGURE 23 PRECISION MEDICINE MARKET CHALLENGES: IMPACT ANALYSIS
  • FIGURE 24 MAJOR BARRIERS CAUSED BY REGULATION AND STANDARDS
  • FIGURE 25 DOWNSIZING COST OF GENOME SEQUENCING
  • FIGURE 26 FLOW CHART OF PRECISION MEDICINE
  • FIGURE 27 VALUE CHAIN ANALYSIS
  • FIGURE 28 PRECISION MEDICINE MARKET: PORTER FIVE FORCE ANALYSIS
  • FIGURE 29 FACTORS IMPACTING THE DEGREE OF COMPETITION
  • FIGURE 30 ROLES AND RESPONSIBILITIES OF HEALTHCARE POLICY MAKERS
  • FIGURE 31 ROLE OF FDA IN PRECISION MEDICINE
  • FIGURE 32 CLASSIFICATION OF MEDICAL DEVICES
  • FIGURE 33 GLOBAL PRECISION MEDICINE MARKET BY ECOSYSTEM PLAYERS
  • FIGURE 34 ROLE OF PHARMACEUTICALS AND BIOTECH COMPANIES
  • FIGURE 35 CHALLENGES FACED BY PHARMA & BIOTECH COMPANIES
  • FIGURE 36 KEY DEVELOPMENTS IN PHARMA & BIOTECH COMPANIES(2015)
  • FIGURE 37 DIAGNOSTIC TESTS BENEFITS FOR STAKEHOLDERS
  • FIGURE 38 CHALLENGES FACED BY DIAGNOSTIC COMPANIES
  • FIGURE 39 BENEFITS OF BIG DATA
  • FIGURE 40 TRANSFORMATION OF MEDICINE
  • FIGURE 41 BASIC INGREDIENTS PROVIDED BY BIG DATA FOR PRECISION MEDICINE
  • FIGURE 42 CHALLENGES FACED BY BIG DATA COMPANIES
  • FIGURE 43 KEY DEVELOPMENTS IN HEALTHCARE IT/BIG DATA COMPANIES(2015)
  • FIGURE 44 OECD RECOMMENDATIONS ON THE GOVERNANCE OF CLINICAL TRIALS
  • FIGURE 45 TYPES OF PRECISION MEDICINE SUB-MARKET
  • FIGURE 46 LIST OF APPROVED COMPANION DIAGNOSTIC DEVICES
  • FIGURE 47 FUNCTION OF BIOMARKERS
  • FIGURE 48 LIST OF BIOBANKS
  • FIGURE 49 BIOBANKS SERVICES
  • FIGURE 50 DEVELOPMENT IN PGX
  • FIGURE 51 MODEL SYSTEMS USED IN PGX
  • FIGURE 52 CHALLENGES OF PGX STUDIES
  • FIGURE 53 FIGURE TITLE MISSING
  • FIGURE 54 MOLECULAR DIAGNOSTICS: APPLICATION
  • FIGURE 55 MOLECULAR DIAGNOSTICS: BENEFITS
  • FIGURE 56 GLOBAL PRECISION MEDICINE MARKET: BY THERAPEUTICS
  • FIGURE 57 TARGET SCOPE OF PRECISION MEDICINE BY CANCER TYPES
  • FIGURE 58 GLOBAL PRECISION MEDICINE MARKET CLASSIFICATION, BY GEOGRAPHY
  • FIGURE 59 KEY DRIVERS FOR PRECISION MEDICINE: NORTH AMERICA
  • FIGURE 60 OBJECTIVES OF THE PRECISION MEDICINE INITIATIVE
  • FIGURE 61 APAC: MARKET CHALLENGES
  • FIGURE 62 ABBOTT: OVERALL FINANCIALS ($BILLION), 2012-2014
  • FIGURE 63 ABBOTT: NET REVENUE BY SEGMENTS ($BILLION), 2012-2014
  • FIGURE 64 ABBOTT: NET REVENUE BY REGION, 2012-2014 ($BILLION)
  • FIGURE 65 ABBOTT: SWOT ANALYSIS
  • FIGURE 66 ALMAC: SWOT ANALYSIS
  • FIGURE 67 ASURAGEN: SWOT ANALYSIS
  • FIGURE 68 BIOMERIEUX: OVERALL FINANCIALS ($MILLION), 2012-2014
  • FIGURE 69 BIOMERIEUX: NET REVENUE BY REGION, 2014
  • FIGURE 70 BIOMERIEUX: NET REVENUE BY SEGMENT, 2014
  • FIGURE 71 BIOMERIEUX: SWOT ANALYSIS
  • FIGURE 72 CEPHEID: OVERALL FINANCIALS, 2012-2014 ($MILLION)
  • FIGURE 73 CEPHEID: NET REVENUE, BY SEGMENTS, 2012-2014 ($MILLION)
  • FIGURE 74 CEPHEID: NET REVENUE, BY REGION, 2012-2014 ($MILLION)
  • FIGURE 75 CEPHEID: SWOT ANALYSIS
  • FIGURE 76 GE CORPORATION: OVERALL FINANCIALS, 2012-2014 ($BILLION)
  • FIGURE 77 GE CORPORATION: NET REVENUE, BY SEGMENTS, 2012-2014 ($MILLION)
  • FIGURE 78 GSK: OVERALL FINANCIALS, 2012-2014 ($BILLION)
  • FIGURE 79 GSK: NET REVENUE BY SEGMENT, 2014 ($BILLION)
  • FIGURE 80 GSK: NET REVENUE BY REGION, 2014 ($BILLION)
  • FIGURE 81 GSK: NET REVENUE BY THERAPEUTICS, 2014 ($BILLION)
  • FIGURE 82 J&J: OVERALL FINANCIALS, 2012 - 2014 ($BILLION)
  • FIGURE 83 J&J: NET REVENUE BY SEGMENT, 2012 - 2014 ($MILLION)
  • FIGURE 84 J&J: NET REVENUE BY REGION, 2012 - 2014 ($MILLION)
  • FIGURE 85 LABCORP: OVERALL FINANCIALS ($MILLION), 2012-2014
  • FIGURE 86 NET REVENUE BY SEGMENTS, 2012-2014($MILLION)
  • FIGURE 87 LABCORP: SWOT ANALYSIS
  • FIGURE 88 MEDTRONIC: OVERALL FINANCIALS, 2012 - 2014 ($MILLION)
  • FIGURE 89 NOVARTIS: OVERALL FINANCIALS, 2012 - 2014 ($BILLION)
  • FIGURE 90 NOVARTIS: NET REVENUE BY REGION, 2014 ($BILLION)
  • FIGURE 91 NOVARTIS: NET REVENUE BY SEGMENT, 2014 ($BILLION)
  • FIGURE 92 PFIZER: OVERALL FINANCIALS, 2012 - 2014 ($BILLION)
  • FIGURE 93 PFIZER: NET REVENUE, BY SEGMENT, 2012-2014 ($MILLION)
  • FIGURE 94 PFIZER: NET REVENUE, BY REGION, 2012-2014 ($BILLION)
  • FIGURE 95 PFIZER : SWOT ANALYSIS
  • FIGURE 96 QIAGEN: OVERALL FINANCIALS ($MILLION), 2012-2014
  • FIGURE 97 QIAGEN: NET REVENUE BY REGION ($MILLION), 2014
  • FIGURE 98 QIAGEN: NET REVENUE BY SEGMENT, 2014
  • FIGURE 99 QUEST: OVERALL FINANCIALS, 2012 - 2014 ($MILLION)
  • FIGURE 100 QUEST: NET REVENUE, BY SEGMENT, 2012 - 2014 ($MILLION)
  • FIGURE 101 QUEST: SWOT ANALYSIS
  • FIGURE 102 ROCHE: OVERALL FINANCIALS, 2012-2014 ($BILLION)
  • FIGURE 103 ROCHE: NET REVENUE, BY SEGMENTS, 2012-2014 ($BILLION)
  • FIGURE 104 ROCHE: SWOT ANALYSIS
  • FIGURE 105 SANOFI PHARMA: OVERALL FINANCIALS, 2012-2014($BILLION)
  • FIGURE 106 SANOFI PHARMA: NET REVENUE, BY SEGMENTS, 2012-2014 ($BILION)
  • FIGURE 107 TAKEDA: OVERALL FINANCIALS, 2012-2014 ($BILLION)
  • FIGURE 108 TAKEDA: SWOT ANALYSIS
  • FIGURE 109 TEVA: OVERALL FINANCIALS, 2012 - 2014 ($BILLION)
  • FIGURE 110 TEVA: NET REVENUE SHARE, BY SEGMENT (2014)
  • FIGURE 111 TEVA: NET REVENUE SHARE, BY REGION (2014)
  • FIGURE 112 TEVA: SWOT ANALYSIS
Back to Top